Objectives: Epidermal growth factor receptor (EGFR) biomarker testing using blood-based liquid biopsies remains challenging due to the low concentration of circulating tumor DNA (ctDNA) in certain plasma samples. The aim of this study is to evaluate the usefulness for EGFR biomarker testing of ctDNA from pleural effusions, cerebrospinal fluids, ascites and pericardial effusions obtained during the clinical management of lung adenocarcinoma patients. Methods: For comparison purposes, 23 paired plasma and body fluid samples were collected from 17 patients with EGFR-positive lung adenocarcinoma. After circulating free DNA (cfDNA) isolation, samples were evaluated for the initial EGFR-sensitizing mutation and the p.T790M resistance mutation by ...
Background: Recent studies have demonstrated the utility of cell-free tumor DNA (ctDNA) from plasma ...
The advances in targeted therapies for lung cancer are based on the evaluation of specific gene muta...
Background: circulating tumor DNA (ctDNA) is a source of tumor genetic material for EGFR testing in ...
Background: Mutations in the epidermal growth factor receptor gene, EGFR, predict response or resist...
The development of methodologies to analyse circulating tumour DNA (ctDNA) in the blood or urine of ...
Over the past decade, substantial developments have been made in the detection of circulating tumor ...
In order to study alternatives at the tissue biopsy to study EGFR status in NSCLC patients, we evalu...
Objective: To determine the predictive and prognostic roles of three blood-based biomarkers: circula...
Lung cancer is the leading cause of cancer-related mortality worldwide. Epidermal growth factor rece...
Supernatant pleural effusions (PE) have shown to be a valuable source for the detection of driver mu...
<div><p>Background</p><p>Circulating tumor DNA (ctDNA) is a promising biomarker for noninvasive epid...
Abstract. Background:. Circulating tumor DNA (ctDNA) is a promising biomarker for non-invasive epide...
Lung cancer is by far the leading cause of cancer death worldwide, with non-small cell lung cancer (...
The feasibility and required sensitivity of circulating free DNA (cfDNA)-based detection methods in ...
Background: We assessed whether serial ctDNA monitoring of plasma and saliva predicts response and r...
Background: Recent studies have demonstrated the utility of cell-free tumor DNA (ctDNA) from plasma ...
The advances in targeted therapies for lung cancer are based on the evaluation of specific gene muta...
Background: circulating tumor DNA (ctDNA) is a source of tumor genetic material for EGFR testing in ...
Background: Mutations in the epidermal growth factor receptor gene, EGFR, predict response or resist...
The development of methodologies to analyse circulating tumour DNA (ctDNA) in the blood or urine of ...
Over the past decade, substantial developments have been made in the detection of circulating tumor ...
In order to study alternatives at the tissue biopsy to study EGFR status in NSCLC patients, we evalu...
Objective: To determine the predictive and prognostic roles of three blood-based biomarkers: circula...
Lung cancer is the leading cause of cancer-related mortality worldwide. Epidermal growth factor rece...
Supernatant pleural effusions (PE) have shown to be a valuable source for the detection of driver mu...
<div><p>Background</p><p>Circulating tumor DNA (ctDNA) is a promising biomarker for noninvasive epid...
Abstract. Background:. Circulating tumor DNA (ctDNA) is a promising biomarker for non-invasive epide...
Lung cancer is by far the leading cause of cancer death worldwide, with non-small cell lung cancer (...
The feasibility and required sensitivity of circulating free DNA (cfDNA)-based detection methods in ...
Background: We assessed whether serial ctDNA monitoring of plasma and saliva predicts response and r...
Background: Recent studies have demonstrated the utility of cell-free tumor DNA (ctDNA) from plasma ...
The advances in targeted therapies for lung cancer are based on the evaluation of specific gene muta...
Background: circulating tumor DNA (ctDNA) is a source of tumor genetic material for EGFR testing in ...